![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 24, 18180-18187, June 16, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Biological Chemistry, The Weizmann Institute
of Science, Rehovot 76100, Israel
Received for publication, January 27, 2000, and in revised form, April 12, 2000
TAFII105, a substoichiometric
coactivator subunit of TFIID, is important for activation of
anti-apoptotic genes by NF- An important issue in control of gene expression is the mechanism
underlying the specificity of the cellular response to extracellular signals. In many cases this response is mediated by specific
transcription factors that are activated by signaling pathways. In
recent years considerable progress has been made in understanding the
molecular mechanism by which signaling pathways regulate transcription
in a variety of cellular systems. Nevertheless some serious problems remain unsolved. For instance, certain transcription factors can be
activated by several distinct signals; yet, the genes induced by these
factors and thus the cellular response vary significantly. The
molecular basis for such differential activation of genes by specific
transcription factors is not yet clear.
One family of transcription factors that is activated by a broad range
of extracellular signals is NF- The transcriptionally active NF- Previously we reported that hTAFII105 serves as coactivator
for the p65/RelA NF- We report here a detailed analysis of TAFII105-p65/RelA
physical and functional interaction. Our findings suggest that
TAFII105 is involved in activation of only a subset of
NF- In Vitro Binding Experiments--
The N-terminal fragments of
TAFII105 were expressed as GST fusion in Escherichia
coli. The recombinant proteins were purified and immobilized on
glutathione-Sepharose beads. 35S-Labeled p65 was
synthesized in vitro by T7 RNA polymerase and rabbit
reticulocytes lysate (Promega TNT kit), and incubated with the
different GST purified proteins in 0.1 M KCl HEMG buffer
(20 mM HEPES, pH 7.9, 100 mM KCl, 12.5 mM MgCl2, 0.2 mM EDTA, 0.1% Nonidet P-40, 1 mM dithiothreitol, 0.2 mM
phenylmethylsulfonyl fluoride) for 2 h at 4 °C. The beads were
washed 3 times with the same buffer and twice with 0.2 M
KCl HEMG buffer. The bound proteins were eluted by boiling in protein
sample buffer 5 min followed by SDS-PAGE and autoradiography.
Nuclear extracts (50 µl, 15 µg/µl) from BJAB cells in 0.1 M HEMG + 0.1% Nonidet P-40 were incubated with GST105 Plasmids--
pCMV-TAFII105,
pCMV-TAFII105 RNA Preparation and RT-PCR Analysis--
Total RNA was prepared
from 293 cells, untreated or treated with TNF- Propagation and Transfection of Cell Lines--
293 cells are
embryonic kidney fibroblasts. 293T cells express SV40 large T-antigen
and therefore allow replication of plasmids bearing SV40 origin. 293, 293T, and HT1080 cell lines were maintained in F-12 Dulbecco's
modified Eagle's medium supplemented with 10% fetal bovine serum.
Transfections were performed using the standard Ca/PO4 method.
For apoptosis assays, 293 cells were transfected in 6-well plates using
a total of 3 µg of plasmid DNA/transfection. Transfections were
performed with 0.2-0.6 µg of p65 DNA; 0.5-0.6 µg of
TAFII105 or TAFII105 Electrophoretic Mobility Shift Assay--
Nuclear extracts were
prepared as described (38) from 293 cells treated with 10 ng/ml TNF-
Purified recombinant GST or GST-TAFII105 fragments (1 µg)
were added to the binding reaction together with the DNA probe and incubated at room temperature for 30 min before loading onto the gel.
Cell Survival Assay--
For the survival analysis 293 cells in
6-well plates were co-transfected with pBabe-GFP reporter plasmid
(50-100 ng) together with the indicated expression vectors (500 ng
each). TNF- Inhibition of Anti-apoptotic Gene Activation by Dominant Negative
Mutant of TAFII105 Involves Direct Interaction with
p65/RelA--
TNF-
Based on the binding experiments we constructed mammalian expression
plasmids carrying mutated variants of TAFII105 Differential Binding of Distinct Forms of NF-
To further test the association of TAFII105 with NF- The TNF-
To examine the possible involvement of TAFII105 in
A20 transcription, we tested whether the endogenous
A20 mRNA level is affected by TAFII105
expression. 293 cells were transiently transfected with wild type or
dominant negative mutant TAFII105 TAFII105 Modulates A20 Promoter Activity--
The
proximal promoter region of the A20 gene contains two
NF-
We then tested the effect of TAFII105 on the TNF- A20 Suppresses TAFII105 In this study we have dissected the molecular mechanism involved
in activation of anti-apoptotic genes by TAFII105 and
p65/RelA. Using biochemical and functional analyses of
TAFII105-NF- Identification of A20 as a gene regulated by
TAFII105, and examination of its anti-apoptotic activity
provided some evidence that the relative affinity of
TAFII105 toward different forms of NF- The expression pattern of TAFII105 and A20 genes
in normal tissues is similar. TAFII105 protein levels are
relatively high in certain B cell lines (26) and in normal murine
lymphoid organs such as spleen and thymus (data not shown). Similarly,
high levels of the murine A20 mRNA were also found in
lymphoid organs, including the thymus and spleen (27). Since NF- The role of TAFs in transcription is not entirely understood. In
vitro transcription studies have clearly indicated that TAFs are
essential activation domains mediators, as well as promoter selectivity
factors (29, 30). On the other hand genetic analysis of some yeast TAFs
indicated that transcription from many promoters is not affected by
their inactivation (31, 32). Moreover, recent studies revealed a
mechanism of transcription activation that is TAF-independent (33, 34)
and that certain TAFs are subunits of additional multiprotein complexes
(35-37). It is therefore apparent that identifying the genes regulated
by TFIID subunits and the mechanism by which these TAFs function
in vivo are critical to understanding the role of TAFs. The
previous finding that TAFII105 is an activation
domain-specific coactivator of p65/RelA required for transcription
activation of anti-apoptotic genes (9) together with the present
characterization of TAFII105 as coactivator of a specific
set of NF- We thank Dr. Sandra Moshonov for careful
reading of the manuscript.
*
This work was supported by grants from the Minerva
Foundation, Germany, the Israel Cancer Research Fund, the Israel Cancer Association, and the Leo and Julia Forcheimer Center for Molecular Genetics.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, April 14, 2000, DOI 10.1074/jbc.M000591200
The abbreviations used are:
TNF, tumor necrosis
factor;
GST, glutathione S-transferase;
RT-PCR, reverse
transcriptase-polymerase chain reaction;
CMV, cytomegalovirus;
GFP, green fluorescent protein;
GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
Interaction of TAFII105 with Selected p65/RelA Dimers
Is Associated with Activation of Subset of NF-
B Genes*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B in response to the cytokine tumor
necrosis factor (TNF)-
. In the present study we have analyzed the
mechanism of TAFII105 function with respect to its
regulation of p65/RelA, a component of NF-
B. We found two
independent p65/RelA-binding domains within the N terminus of
TAFII105. One of these domains appears to be crucial for
TAFII105-mediated anti-apoptotic gene activation in
response to TNF-
. Analysis of the interaction between
TAFII105 and different NF-
B complexes has revealed
substantial differences in the affinity of TAFII105 toward
different p65/RelA-containing dimers. We have identified the TNF-
induced anti-apoptotic A20 gene as a target gene of
TAFII105. A20 has a differential protective
effect on cell death induced by TNF-
in the presence of either the
dominant negative mutant of TAFII105
(TAFII105
C) or the superdominant I
B
. The results
suggest that the inhibitory effect of TAFII105
C on
NF-
B-dependent genes is restricted to a subset of
anti-apoptotic genes while the effect of I
B
is more general.
Thus, an interaction between NF-
B and a specific coactivator is
important for specifying target gene activation.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B. The signals include inflammatory
cytokines, chemokines, interferons, major histocompatibility complex
proteins, growth factors, cell adhesion molecules, viruses, and certain
stress signals (1). NF-
B transcription factors also regulate
apoptosis. They mediate activation of survival genes that protect cells
from apoptosis induced by various agents such as the cytokine
TNF-
1 (2), certain
oncogenes (3, 4), ionizing radiation, and chemotherapeutic agents (5).
However, under some circumstances, NF-
B has the opposite effect, and
can activate genes that promote apoptosis (6, 7).
B is a dimeric complex composed of
members of the Rel family of proteins, p65/RelA, p50, c-Rel, RelB, and
p52 (8). In most cells, these factors are localized in the cytoplasm
bound by I
B proteins, a family of inhibitory proteins that prevents
nuclear transport of NF-
B proteins. Signals that activate NF-
B,
such as cytokines or stress, induce phosphorylation of I
B and its
subsequent degradation, thereby releasing NF-
B. NF-
B then
translocates into the nucleus and activates its target genes (1).
B subunit and is required for activation of
certain anti-apoptotic genes in human 293 cells (9). This function of
hTAFII105 involves direct interaction between the p65
subunit of NF-
B and the N-terminal domain of hTAFII105.
In addition to hTAFII105, numerous reports have indicated
that the coactivator protein CBP and its homolog p300 are also involved in transcription activation by p65 subunit of NF-
B (10, 11). Likewise, other TFIID subunits such as hTAFII250,
hTAFII80, and hTAFII28 have been reported to
bind p65/RelA (12). Most recently, p65 was also found to interact
specifically with the composite coactivator ARC/DRIP and this complex
supports NF-
B dependent transcriptional activation in
vitro (13). At present it is not clear whether these coactivator
complexes display redundant functions, or whether transcription
activation by NF-
B utilizes each of these complexes sequentially.
B genes and this selective effect of TAFII105 is
associated with preference for selected forms of p65/RelA complexes.
These results reveal the importance of combinatorial interactions
between activators and coactivators for differential target gene activation.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
C
or with GST beads as described above. After the washes, bound proteins were eluted with 1 M NaCl HEMG, loaded on SDS-PAGE, and
analyzed by Western blot, using anti-p65 and anti-p50 antibodies (Santa Cruz).
C-(1-552) and
pCMV-TAFII105
C-(1-452) were previously described (9).
TAFII105
C-(
453-471) was constructed by ligating a
PCR fragment encoding amino acid 472-552 to the 3' of
TAFII105
C-(1-452) digested with HindIII and
filled in. GST-TAFII105
C-(1-552) was described
previously. GST-TAFII105-(211-358) was constructed by
ligating a Sau3A-PvuII fragment into
BamHI-SmaI of pGEX2TK.
GST-TAFII105-(350-445) was constructed by ligating an
HaeIII fragment-(1048-1335) into StuI site of
pGEX2TKN. The DNA encoding amino acids 411-552 was generated by PCR
and cloned into NcoI-EcoRI sites of pGEX2TKN.
GST-TAFII105-(411-445) was generated by digesting 411-552
with NcoI and HaeIII and ligating into pGEX2TKN
digested with NcoI and StuI. 445-552 is an
HaeIII-EcoRI fragment from
GST-TAFII105-(1-552) cloned into
StuI-EcoRI of pGEX2TKN. The fragment encoding
amino acids 472-552 was generated by PCR and cloned into the
SmaI-BamHI digest of pGEX3. The cDNA encoding the A20 gene (2.4 kilobases) was obtained by PCR from human
Daudi cDNA library. The 5' oligonucleotide was
AGTCCTTCCTCAGGCTTTGTA; and the 3' oligonucleotide,
CCCACTTCTTGCAGGAGGTGA. To construct the A20 expression
plasmid, CMV-A20, the cDNA was cloned in pCGN vector in
SmaI site. The insert was sequenced and expression was verified by Western blot using anti-hemagglutinin antibody (data not
shown). To generate the A20 luciferase reporter plasmid, a PstI fragment from A20-CAT (a gift of Dr. Dixit,
V), spanning the proximal promoter region, was cloned in the
PstI site of pLuc, a promoter-less reporter plasmid. The
NF-
B deleted A20 promoter was generatd by PCR.
for 1-3 h, using
Trizol reagent (Life Technologies, Inc.), according the manufacturers
instructions. To determine the effect of TAFII105 and I
B
on A20 mRNA, subconfluent 293T cells in 100-mm plates
were transfected with 3.5 µg of the different expression plasmids in
a total of 10 µg of DNA. RNA preparations were treated with RQ1 DNase
I (Promega) to avoid contamination of genomic and transfected DNAs.
First strand cDNA and PCR amplification were performed in a single
tube using the Access RT-PCR System (Promega). The oligonucleotides
used for RT-PCR are: GAPDH forward, TTGTCATCAATGGAAATCCC; GAPDH reverse,
TGTCGCTGTTGAAGTCAG; A20 forward, CACACAAGGCACTTGGATCC; A20
reverse, CAGGATGTTCTTGCAGGAGG; A1 forward, CAAGACTTTGCTCTCCACCA; A1 reverse, GGCAATCGTTTCCATATCAGT;
MnSOD forward, ATGTTACAGCCCAGACAGC; MnSOD
reverse, TTCAATCACTTGCCCAATAA; IEX-1L forward,
AGGCAACTTGAACTCAGAACA; IEX-1L reverse, CTCGCAGCCACCCTAA; Bcl-xL forward, ACCCATCCTGGCACCTGGCA; Bcl-xL
reverse, GGATCCAAGGCTCTAGGTGG; cIAP2 forward,
GAAATAAGGGAAGAGGAGAG; cIAP2 reverse, TACGAACTGTACCCTTGATT. Oligonucleotides used as probes for the RT-PCR products were
GAPDH, TGAAGCAGGCGTCGGAGGGC, and A20, AGATCCCTCGCGGCTCGTCC.
C DNA; 0.5-0.6 of I
B
DNA and 0.3-0.5 µg of A20. Reporter assays were performed
as described previously (9). The amount of the different activator
plasmids varied between 5 and 20 ng, and TAFII105 plasmid
used was 300-500 ng/well. In each transfection the amount of CMV
containing plasmid was kept constant. Luciferase activity was
determined according to the manuacturer's protocol (Promega).
for 1 h, or 48 h after transfection of NF-
B subunits as
indicated. A double stranded oligonucleotide, containing the NF-
B
site was labeled with Klenow fragment of DNA polymerase I as probe. The
oligonucleotides sequence is: 5'-GATCCAGAGGGGACTTTTCCGAGAG-3'; 5'-GATCCTCTCGGAAAGTCCCCTCTG-3'.
(5 ng/ml) was added 12-24 h after transfection and
48-60 h after transfection cells were visualized by microscope for
green fluorescent cell detection. The number of GFP cells was
determined by counting three different randomly chosen fields.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
induction stimulates a protein synthesis
independent apoptotic response. In cells resistant to the TNF-
cytotoxic effect, it also induces expression of proteins that block
apoptosis and this activation is mediated by NF-
B.
TAFII105 interacts with the p65/RelA subunit of NF-
B and
is involved in activation of NF-
B-dependent
anti-apoptotic genes in human 293 cells (9). To examine the mechanism
of TAFII105 action with respect to NF-
B, we mapped the
domain within the TAFII105 N terminus directing the
interaction with p65/RelA. For this purpose various fragments of
TAFII105 N-terminal domain were cloned in front of the
glutathione S-transferase (GST) gene (Fig.
1A). The different fusion
proteins were purified from E. coli and used for an in
vitro pull-down assay with 35S-labeled p65/RelA
subunit of NF-
B (Fig. 1B). This analysis revealed two
p65/RelA-binding regions within TAFII105 (Fig. 1B,
lanes 4 and 6). Quantitation of the relative binding
indicated that the C-terminal-binding domain interacts with p65/RelA
more efficiently. Further deletion analysis of the major
p65/RelA-binding site indicated that the amino acid residues between
445 and 472 are crucial for p65 binding (lanes 7-12).

View larger version (29K):
[in a new window]
Fig. 1.
Mapping of p65-binding domain on
TAFII105. A, schematic representation of
TAFII105 deletion mutants derived from its N-terminal
region. These mutants were analyzed for p65/RelA binding as shown in
B. The relative binding was determined by normalizing p65
binding activity to the amount of recombinant protein used and is shown
on the right as + or
. B, pull-down binding
assay using 35S-labeled p65/RelA and purified fragments of
TAFII105 (indicated by their amino acid residues) fused to
GST and bound to glutathione beads. As control, a similar reaction was
performed using the same beads bound by GST (lanes 2 and
8). The input lanes represent 10% of p65 used for the
binding assay.
C, a
dominant negative form of TAFII105 (Fig.
2A). We next analyzed the
inhibitory effect of TAFII105
C mutants on
p65/RelA-mediated transcription activation in 293 cells. As shown in
Fig. 2C, the TAFII105
C mutant lacking the
major p65-binding domain is a less potent inhibitor of p65/RelA
transcription activity than the mutants carrying p65-binding domain
(columns 3-5). Next, we examined the effect of these
mutants on NF-
B-dependent anti-apoptotic gene activation
in response to the cytokine TNF-
. We used the green fluorescent
protein (GFP) expression assay to measure cell viability of transfected
cells (Fig. 2D). A significant reduction in cell viability
in response to TNF-
is observed in cells expressing any form of
TAFII105
C containing the p65/RelA binding (Fig.
2D) as occurred also in cells expressing superdominant I
B
(Fig. 7). We confirmed that this effect is related to programmed cell
death by analyzing the genomic DNA of cells expressing
TAFII105
C and induced with TNF-
(Fig. 2E).
The DNA ladder characteristic to apoptotic response is clearly observed
in cells expressing TAFII105
C and stimulated with
TNF-
(lane 5) while no DNA fragmentation appeared in
TNF-
-induced 293 cells transfected with empty expression vector
(lane 3). Notably, the survival of 293 cells seems to be
partially dependent on the constitutive nuclear NF-
B activity since
expression of either superdominant I
B (Fig. 7) or
TAFII105
C (Fig. 2D) reduces by 20-30% cell
survival of transfected cells without providing external apoptotic
signal. TAFII105
C lacking the p65/RelA-binding region failed to inhibit the basal as well as TNF-
induced anti-apoptotic gene activation and to sensitize cells to TNF-
cytotoxic effect (Fig. 2D, columns 7-10). These results suggest that the
p65-binding domain of TAFII105 is crucial for its
anti-apoptotic function.

View larger version (25K):
[in a new window]
Fig. 2.
Functional analysis of
TAFII105
C mutants.
A, schematic representation of TAFII105
C
derived mutants cloned in mammalian expression plasmids. B,
immunoblot of 293 cells transfected with the either empty vector
(lane 1) or different TAFII105
C mutants
(lanes 2-5) using anti-hemagglutinin antibody.
C, effect of TAFII105
C mutants on
p65-dependent transcription activation. Human 293 cells
were co-transfected with an NF-
B-dependent luciferase
reporter, together with an empty expression plasmid (column
1) or p65 (column 2), or p65 with different
mutants of TAFII105
C (columns 3-5).
Luciferase activity was monitored 24 h post-transfection.
D, survival analysis of cells transfected with the different
TAFII105
C mutants and induced by TNF-
. 293T cells
were co-transfected with CMV-GFP reporter plasmid and an empty vector
or the expression plasmids described in A. 24 h after
transfection TNF-
was applied to the cells and 48 h later,
fluorescent cells in five randomly chosen fields were counted. These
data are representative of three independent transfection experiments
with similar results. E, 293T cells were transfected with an
empty expression plasmid (lanes 2 and 3) and
TAFII105
C (4 and 5) and either untreated (lanes
2 and 4) or treated with 15 ng/ml TNF-
(lanes
3 and 5). Transfection efficiency was estimated to be
~80%. Genomic DNA was extracted 48 h after transfection and
analyzed by 1.8% agarose gel. M indicates DNA size marker
(lane 1).
B to
TAFII105--
Transcription activation through the NF-
B
regulatory site can be directed by different dimers of the NF-
B
family. p65/RelA can dimerize with all the family members. A possible
regulatory mechanism for specifying gene transcription would be if
various combinations of NF-
B dimers display differential coactivator binding. We have compared the relative binding of TAFII105
to different forms of NF-
B complexes: constitutive, TNF-
induced, and transfected NF-
B dimers. Nuclear extracts, prepared from control, TNF-
-induced, and NF-
B-transfected 293 cells, were used
in electrophoresis mobility shift assays with a labeled oligonucleotide specific to the NF-
B-binding site. The DNA binding reaction was incubated with TAFII105 recombinant fragment which included
the major p65-binding domain (GST-(445-551)). A mutated
TAFII105 protein lacking the p65-binding region
(GST-(470-551)) was used as a control (Fig.
3). As expected, strong NF-
B binding
activity was detected following TNF-
induction or transfection of
various NF-
B members (Fig. 3, A and C).
TNF-
induced the formation of two major NF-
B binding complexes
(Fig. 3A). Using antibodies directed against different
subunits of the NF-
B family, we identified the low mobility complex
as a homodimer of p65 and the faster migrating complex as a p65/p50
subunit heterodimer (Fig. 3B). Interestingly, among the
TNF-
induced NF-
B complexes, the p65/p65 homodimer but not the
p65/p50 complex formed a ternary supershifted complex with the wild
type although not with the p65-binding site-deleted TAFII105 peptide (Fig. 3A, lanes 6-9). The
formation of the supershifted complex is accompanied with 53%
reduction in the intensity of p65/p65 complex and less significant
reduction in the intensity of p65/p50 complex (5%) as determined by
densitometric analysis (see also Fig. 3A, short exposure).
Similarly, the constitutive NF-
B complex which is also composed of a
p65 homodimer (data not shown), bound TAFII105 efficiently
(Fig. 3A, lanes 10-12). Incubation of p65 homodimeric
complex derived from transfected cells with the GST-(445-552)
TAFII105 fragment resulted in a weaker p65 complex (Fig.
3A, lane 5, 38% reduction). A weak ternary supershifted complex could be seen only after prolonged exposure (data not shown).
It is likely that this ternary complex is not stable under the
electrophoresis conditions indicating this type of p65 homodimeric complex bound TAFII105 less efficiently than native p65/p65
complex such as the TNF-
induced or the constitutive p65/p65 complex (Fig. 3A compare lanes 5-9 and 12).
This suggests that the affinity of TAFII105 for the p65
homodimer may also be regulated, perhaps by signaling pathways. p65/p50
or p50/p50 dimers derived from transfected cells were impaired in
TAFII105 association in this assay (Fig. 3C, lanes
3-6). In contrast, the p65/c-Rel heterodimer did bind to
TAFII105 (Fig. 3C, lanes 7-9).

View larger version (39K):
[in a new window]
Fig. 3.
Differential binding of TAFII105
to different forms of NF-
B. A,
electrophoresis mobility shift assay using the NF-
B-binding site as
DNA probe. Nuclear extracts were prepared from control (lanes
1 and 10-12 shown after longer exposure), p65
transfected (lanes 2-5), and 1 h TNF-
-treated 293 cells (lanes 6-9). Purified recombinant GST or GST fused to
TAFII105 fragments were added to the DNA binding reactions
as indicated at the top each lane. B,
identification of NF-
B subunits of the TNF-
induced complexes
using NF-
B specific antibodies as indicated. C, analysis
of TAFII105 binding by transfected p50/p50, p65/p50, and
p65/c-Rel complexes. Antibodies against p65 and c-Rel were used to
confirm the presence p65 and c-Rel in the cell extract prepared from
p65 + c-Rel-transfected cells (data not shown).
B
proteins we used nuclear extract prepared from the B cell line BJAB. This extract was incubated with immobilized TAFII105 (N
terminus, amino acid 1-552) and bound NF-
B subunits were analyzed
by Western blot using antibodies specific to either p65 or p50 subunits
of NF-
B. As shown in Fig. 4, only p65
but not p50 was specifically retained on TAFII105
containing beads. Since this BJAB extract contains p65/p50 complex
(data not shown), this experiment further confirms the preference of
TAFII105 to p65 dimers devoid of the p50 subunit. Taken
together these findings indicate that NF-
B dimers vary in their
affinity to TAFII105.

View larger version (45K):
[in a new window]
Fig. 4.
Selective interaction of
hTAFII105 with p65 homodimer. Purified
TAFII105 protein (GST105
C, amino acid 1-552) fused to
GST and bound to glutathione-Sepharose beads, or control GST-containing
beads were used for binding reaction with nuclear extract prepared from
the human B cell line BJAB. The bound proteins were eluted by high salt
and subjected to SDS-polyacrylamide gel electrophoresis followed by
Western blot analysis using anti-p65 or anti-p50 antibodies. Input
lanes represent 10% of the total nuclear extract used for the
binding.
Inducible Anti-apoptotic Gene A20 Is a Transcriptional
Target of TAFII105--
Numerous studies have indicated
that NF-
B anti-apoptosis involves activation of several genes that
inhibit, partially or fully, the TNF-
cell death response. In an
attempt to identify anti-apoptotic gene(s) targeted by
TAFII105 in 293 cells, we first examined the expression of
these genes in response to short term TNF-
induction using RT-PCR.
We analyzed the manganese superoxide dismutase gene (14), the
A20 gene (15), cIAP2, a member of inhibitor of apoptosis
family of genes (16, 17), the bcl-2 homolog A1 gene (18) and
IEX-1L (19). We also tested the expression of
BclXL, an anti-apoptotic gene that is not induced by
TNF-
and the housekeeping gene GAPDH. Of all these genes,
the A20 gene was rapidly and most significantly induced by
TNF-
(Fig. 5A). The
IEX-1L was moderately induced and the rest of the genes
analyzed were not induced at all by TNF-
. The finding that only two
out of the five NF-
B-dependent anti-apoptotic genes that
we analyzed are TNF-
inducible in 293 cells suggests that in
different cell types, resistance to TNF-
induced cell death is
conferred by different sets of anti-apoptotic genes.

View larger version (26K):
[in a new window]
Fig. 5.
A, analysis of TNF-
inducible genes
in human 293 cells. 293 cells were treated with TNF-
(5 ng/ml) for
1 h and expression of the indicated genes was determined by
RT-PCR. These results are representative of two to four experiments
with similar results. B, effect of TAFII105
expression on mRNA level of the TNF-
induced A20
gene. Human 293T cells were transfected with the indicated expression
plasmids (transfection efficiency is above 50%). 24 h
post-transfection cells were treated with TNF-
for 1 h followed
by RNA extraction and RT-PCR reaction using human A20 or
GAPDH specific primers. The identity of the PCR products was
confirmed by southern hybridization (data not shown). C,
quantitation of A20 RT-PCR product level normalized to
GAPDH products. These results are average of three
independent transfection experiments with similar results.
C and treated with
TNF-
for 1 h. RNA was extracted and used to monitor the level
of the A20 mRNA by RT-PCR reaction. TAFII105
expression elevates the TNF-
-induced A20 mRNA whreas
TAFII105
C inhibits it (Fig. 5, B and
C). The effect of TAFII105 is specific since it
had no significant effect on the level of GAPDH mRNA. In
agreement with a previous study (20), we found that the transcription of the A20 gene is NF-
B dependent, since expression of
superdominant I
B similarly inhibited A20 transcription.
Thus, induction A20 mRNA by TNF-
involves NF-
B
proteins and the TFIID complex containing TAFII105.
B-binding sites that are crucial for the TNF-
inducibility of
this gene (20). To further test the involvement of the
TAFII105·TFIID complex in A20 transcription we
determined the effect of TAFII105 on the promoter activity
of the A20 gene. 293 cells were transfected with a
luciferase reporter gene under the control of the A20
promoter together with p65 subunit of NF-
B and TAFII105.
TAFII105 enhances both, basal and p65 induced activity of
the A20 promoter (Fig. 6A, columns 3 and
7), and this induction requires the presence of NF-
B
proteins as TAFII105 fails to induce the A20
promoter activity in the presence of the NF-
B inhibitor protein,
I
B (columns 5 and 9) or when NF-
B sites
were deleted from the promoter (columns 11-14). We also
examined the effect of the dominant negative mutant of
TAFII105 on the A20 promoter activity.
TAFII105
C inhibited the basal and p65 induced activity
of the A20 promoter (compare columns 1 and
4 to 6 and 10). The inhibition of
basal and induced A20 promoter activity by
TAFII105
C is similar to that of I
B (columns
5 and 8).

View larger version (18K):
[in a new window]
Fig. 6.
The effect of TAFII105 on the
A20 promoter activity. A, human 293 cells (in 24-well dish) were co-transfected with wild type or
NF-
B-deleted A20-dependent reporter plasmid
(25 ng) together with either empty expression vector or the following
expression plasmids: TAFII105 (150 ng, columns 3, 5, 7, 9, 13, and 14), p65 (3-5 ng, columns 6-10,
12, and 14), 500 ng of I
B
(columns 2, 5, 8, and 9), and 500 ng of TAFII105
C
(columns 4 and 10). The amount of CMV derived
vector in each transfection assay was kept constant. B,
similar transfection experiment using TNF-
instead of p65. 24 h
after transfection TNF-
(1.5-3 ng/ml) was added and 3 h later
cells were harvested. C, similar transfection assays as in
B using HT1080 cells. The results presented are average of
three independent transfection assays with similar results.
induced activity of the A20 promoter. Here again
TAFII105 enhances the TNF-
induced promoter activity
(Fig. 6B, column 3) and TAFII105
C abolished
this induction (column 6). In the presence of I
B, or when
the NF-
B-binding site is deleted, TAFII105 fails to
enhance A20 promoter activity (column 5)
indicating that enhancement of TNF-
stimulated promoter activity by
TAFII105 requires the NF-
B proteins. Similarly,
TAFII105 further stimulated the activity of the
A20 promoter in the human fibroblast cell line HT1080 (Fig. 6C) indicating that the effect of TAFII105 on
the A20 promoter is not restricted to 293 cells.
C-induced Cell Death More
Efficiently than I
B
-induced Cell Death--
The early TNF-
induced gene A20 is a zinc finger-containing protein
involved in modulation of TNF-
signaling (21) and inhibition of
apoptotic proteases (22). A20 confers resistance to TNF-
cytotoxicity and to other apoptotic signals in certain cell types (15,
23-25). Since promotion of cell death by TAFII105
C and
I
B
is associated with inhibition of anti-apoptotic genes such as
A20, we tested whether overexpression of the A20
gene would protect cells from the apoptotic effect of
TAFII105
C or I
B
. Cells were transfected with
expression plasmids of TAFII105
C or superdominant
I
B
along with the green fluorescent protein plasmid and viability
of the transfected cells was measured 48 h after addition of
TNF-
. Similar marked reductions in cell survival were observed in
cells expressing TAFII105
C or superdominant I
B
, in
response to TNF-
(Fig. 7A, columns 4 and
6, and B, middle panel). However, when the
A20 gene was co-transfected with TAFII105
C, the TNF-
-induced apoptosis was overcome and cell survival was significantly increased (Fig. 7A, compare columns
4 and 8, and B). It was noted that the
A20 gene only partially blocked the TNF-
-induced
apoptosis in cells expressing superdominant I
B
(compare
columns 6 to 10). This suggests that full rescue
from I
B
-mediated apoptosis requires expression of some other
anti-apoptotic genes besides A20. Furthermore, the
differential protective effect of A20 indicates that the
inhibitory effect of TAFII105
C on NF-
B anti-apoptotic
genes is more restricted than that of I
B
which is known to be a
general inhibitor of NF-
B. Thus, it can be concluded that
TAFII105 mediates activation of only a subset of
NF-
B-dependent genes in response to TNF-
. This notion
is consistent with the selective binding of TAFII105 by
just one of the NF-
B complexes induced by TNF-
.

View larger version (54K):
[in a new window]
Fig. 7.
Effect of A20 expression on
survival of TNF-
-induced cells.
A, human 293T cells were co-transfected with expression
plasmids as indicated in the bottom of each column, and the
GFP expression plasmid. Twenty-four hours after transfection TNF-
was added and 48 h later green fluorescent cells from three fields
were counted. These results are average of four independent
transfection experiments. B, representative pictures of
TAFII105
C transfected 293 cells rescued from apoptosis
by A20 expression.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B interaction together with the
characterization of a gene regulated by TAFII105 and
NF-
B, we show that TAFII105 functions in a selective
manner with respect to NF-
B. TAFII105 exhibits high
affinity to NF-
B dimers composed of p65/p65 and p65/c-Rel subunits;
interaction with heterodimer composed of p65/50, however, is
significantly less efficient. Since in the cell the amount of
TAFII105-TFIID complex is limited (26), it is likely that
it will be targeted only by those NF-
B complexes for which it
displays high affinity. Genes activated by the p65/p50 complex are,
therefore, less likely to be regulated by TAFII105.
B dimers
contributes to differential gene activation by NF-
B. The results
showed that the TNF-
-induced mRNA level of the endogenous
A20 gene is enhanced by TAFII105 expression and reduced by both dominant negative mutants of TAFII105 and
I
B
. Consistent with the cell death protective function of the
A20 gene, its expression in 293 cells shields them against
apoptosis induced by the mutant TAFII105 protein and
TNF-
, suggesting that down-regulation of A20 by
TAFII105
C is associated with the cell death response.
Since the A20 gene only partially suppresses apoptosis induced by superdominant I
B
and TNF-
, full protection requires additional genes activated by NF-
B as reported elsewhere (17). Importantly, the differential effect of A20 on
TAFII105
C and I
B
indicates that the inhibitory
effect of TAFII105
C on NF-
B activity is not as
general as is that of I
B
, and is directed to certain specific
genes. These results are compatible with the selective association of
TAFII105 with one of NF-
B complexes induced by TNF-
in 293 cells. Hence, it is conceivable that NF-
B can utilize
alternative pathways for transcription activation. Such alternative
pathways might be dependent on the structure and composition of the
target gene promoter as well as on the existence of other coactivators
for NF-
B proteins. This idea is consistent with recent studies
showing that transcription activation by the p65/RelA subunit of
NF-
B can be mediated by multiple and distinct coactivators (9-13).
It has been suggested that different coactivator complexes may act
sequentially during the transcription activation process (28). Our
results also raise the possibility that different coactivator subunits
may function in the context of different target genes, suggesting that
activator-coactivator interaction is important for specifying gene
activation. The suggested mechanism provides a partial explanation as
to how NF-
B containing complex activates different arrays of genes
in response to different extracellular signals.
B is
constitutively active in many lymphoid cell types, it is possible that
large amounts of NF-
B·TAFII105·TFIID complex in
lymphoid cells are responsible for the significant expression of the
A20 gene in these cells.
B genes, is an important step toward understanding how
TAFs work and what role they play in specific gene regulatory pathways.
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
Incumbent of the Martha S. Sagon Career Development Chair. To whom
correspondence should be addressed. Tel.: 972-8-9342117; Fax:
972-8-934-4118; E-mail: bcrivka@wiccmail.weizmann.ac.il.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Baldwin, A. S., Jr.
(1996)
Annu. Rev. Immunol.
14,
649-683
2.
Van Antwerp, D. J.,
Martin, S. J.,
Verma, I. M.,
and Green, D. R.
(1998)
Trends Cell Biol.
8,
107-111
3.
Mayo, M. W.,
Wang, C.-Y.,
Cogswell, P. C.,
Rogers-Graham, K. S.,
Lowe, S. W.,
Der, C. J.,
and Baldwin, A. S., Jr.
(1997)
Science
278,
1812-1815
4.
Reuther, J. Y.,
Reuther, G. W.,
Cortez, D.,
Pendergast, A. M.,
and Baldwin, A. S., Jr.
(1998)
Genes Dev.
12,
968-981
5.
Wang, C-Y.,
Mayo, M. W.,
and Baldwin, A. S., Jr.
(1996)
Science
274,
784-787
6.
Sonenshein, G. E.
(1997)
Semin. Cancer Biol.
8,
113-119
7.
Foo, S. Y.,
and Nolan, G. P.
(1999)
Trends Genet.
15,
229-235
8.
Verma, I. M.,
Stevenson, J. K.,
Schwarz, E. M.,
Van Antwep, D.,
and Miyamoto, S.
(1995)
Genes Dev.
9,
2723-2735
9.
Yamit-Hezi, A.,
and Dikstein, R.
(1998)
EMBO J.
17,
5161-5169
10.
Perkins, N. D.,
Felzien, L. K.,
Betts, J. C.,
Leung, K.,
Beach, D. H.,
and Nabel, G. J.
(1997)
Science
275,
523-527
11.
Gerritsen, M. E.,
Williams, A. J.,
Neish, A. S.,
Moore, S.,
Shi, Y.,
and Collins, T.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2927-2932
12.
Guermah, M.,
Malik, S.,
and Roeder, R. G.
(1998)
Mol. Cell. Biol.
18,
3234-3244
13.
Naar, A. M.,
Beaurang, P. A.,
Zhou, S.,
Abraham, S.,
Solomon, W.,
and Tjian, R.
(1999)
Nature
398,
828-832
14.
Wong, G. H.,
Elwell, J. H.,
Oberley, L. W.,
and Goeddel, D. V.
(1989)
Cell
58,
923-931
15.
Opipari, A. W.,
Hu, J. R.,
Yabkowitz, R.,
and Dixit, V. M.
(1992)
J. Biol. Chem.
267,
12424-12427
16.
Chu, Z.-L.,
McKinsey, A. T.,
Liu, L.,
Gentry, J. J.,
Malim, M. H.,
and Ballard, D. W.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10057-10062
17.
Wang, C. Y.,
Mayo, M. W.,
Korneluk, R. G.,
Goeddel, D. V.,
and Baldwin, A. S., Jr.
(1998)
Science
281,
1680-1683
18.
Karsan, A.,
Yee, E.,
and Harlan, J. M.
(1996)
J. Biol. Chem.
271,
27201-27204
19.
Wu, M. X.,
Ao, Z.,
Prasad, K. V. S.,
Wu, R.,
and Schlossman, S. F.
(1998)
Science
281,
998-1001
20.
Krikos, A.,
Laherty, C. D.,
and Dixit, V. M.
(1992)
J. Biol. Chem.
267,
17971-17976
21.
Song, H. Y.,
Rothe, M.,
and Goeddel, D. V.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
6721-6725
22.
Wissing, D.,
Mouritzen, H.,
and Jaattela, M.
(1998)
Free Radic. Biol. Med.
25,
57-65
23.
Jaattela, M.,
Mouritzen, H.,
Elling, F.,
and Bastholm, L.
(1996)
J. Immunol.
156,
1166-1173
24.
Sarma, V.,
Lin, Z.,
Clark, L.,
Rust, B. M.,
Tewari, M.,
Noelle, R. J.,
and Dixit, V. M.
(1995)
J. Biol. Chem.
270,
12343-12346
25.
Fries, K. L.,
Miller, W. E.,
and Raab-Traub, N.
(1996)
J. Virol.
70,
8653-8659
26.
Dikstein, R.,
Zhou, S.,
and Tjian, R.
(1996)
Cell
87,
137-146
27.
Tewari, M.,
Wolf, F. W.,
Seldin, M. F.,
O'Shea, K. S.,
Dixit, V. M.,
and Turka, L. A.
(1995)
J. Immunol.
154,
1699-706
28.
Cosma, M. P.,
Tanaka, T.,
and Nasmyth, K.
(1999)
Cell
97,
299-311
29.
Verrijzer, C. P.,
and Tjian, R.
(1996)
Trends Biochem. Sci.
21,
338-342
30.
Hoffmann, A.,
Oelgeschlager, T.,
and Roeder, R. G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
8928-8935
31.
Moqtaderi, Z.,
Bai, Y.,
Poon, D.,
Weil, P. A.,
and Struhl, K.
(1996)
Nature
383,
188-191
32.
Walker, S. S.,
Reese, J. C.,
Apone, L. M.,
and Green, M.
(1996)
Nature
383,
185-188
33.
Koleske, A. J.,
and Young, R. A.
(1995)
Nature
368,
466-469
34.
Oelgeschlager, T.,
Tao, Y.,
Kang, Y. K.,
and Roeder, R. G.
(1998)
Mol. Cell
1,
25-31
35.
Grant, P. A.,
Schieltz, D.,
Pray-Grant, M. G.,
Steger, D. J.,
Reese, J. C.,
Yates, J, R.,
and Workman, J. L.
(1998)
Cell
94,
45-53
36.
Ogryzko, V. V.,
Kotani, T.,
Zhang, X.,
Schlitz, R. L.,
Howard, T.,
Yang, X. J.,
Howard, B. H.,
Qin, J.,
and Nakatani, Y.
(1998)
Cell
94,
35-44
37.
Wieczorek, E.,
Brand, M.,
Jacq, X.,
and Tora, L.
(1998)
Nature
393,
187-191
38.
Schreiber, E.,
Matthias, P.,
Muller, M. M.,
and Schaffner, W.
(1989)
Nucleic Acids Res.
17,
6419
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
V. Gupta, G. Yeo, H. Kawakubo, V. Rangnekar, P. Ramaswamy, T. Hayashida, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian-Inhibiting Substance Induces Gro-{beta} Expression in Breast Cancer Cells through a Nuclear Factor-{kappa}B-Dependent and Smad1-Dependent Mechanism Cancer Res., March 15, 2007; 67(6): 2747 - 2756. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Wieland, N. Nehmann, D. Muller, H. Eibel, U. Siebenlist, J. Suhnel, P. F. Zipfel, and C. Skerka Early growth response proteins EGR-4 and EGR-3 interact with immune inflammatory mediators NF-{kappa}B p50 and p65 J. Cell Sci., July 15, 2005; 118(14): 3203 - 3212. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. McInnis, A. Britain, R. N. Lausch, and J. E. Oakes Synthesis of {alpha}-Chemokines IP-10, I-TAC, and MIG Are Differentially Regulated in Human Corneal Keratocytes Invest. Ophthalmol. Vis. Sci., May 1, 2005; 46(5): 1668 - 1674. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Koyanagi, M. Hijikata, K. Watashi, O. Masui, and K. Shimotohno Centrosomal P4.1-associated Protein Is a New Member of Transcriptional Coactivators for Nuclear Factor-{kappa}B J. Biol. Chem., April 1, 2005; 280(13): 12430 - 12437. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Ritchie, R. A. Fillmore, R. N. Lausch, and J. E. Oakes A Role for NF-{kappa}B Binding Motifs in the Differential Induction of Chemokine Gene Expression in Human Corneal Epithelial Cells Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2299 - 2305. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. O. Hassa, C. Buerki, C. Lombardi, R. Imhof, and M. O. Hottiger Transcriptional Coactivation of Nuclear Factor-{kappa}B-dependent Gene Expression by p300 Is Regulated by Poly(ADP)-ribose Polymerase-1 J. Biol. Chem., November 14, 2003; 278(46): 45145 - 45153. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hochheimer and R. Tjian Diversified transcription initiation complexes expand promoter selectivity and tissue-specific gene expression Genes & Dev., June 1, 2003; 17(11): 1309 - 1320. [Full Text] [PDF] |
||||